AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01157741 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: C-C
Description: Mx as H-C plus positioning follow up in the community clinic
Study NCT01157741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C-SF
Description: As C-C but with additional supplementary food (SF) (C-SF)
Study NCT01157741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: As C-C with additional psychosocial stimulation (PS) (C-PS)
Description: Giving psychosocial stimulation
Study NCT01157741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: As C-C but with both SF & PS (C-SF+PS)
Description: Giving both SF \& PS
Study NCT01157741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H-C
Description: Follow-up at Hospital
Study NCT03990363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Study treatments will be titrated in 3 steps for target low dose (3 mg), intermediate dose ( 7.5 mg) and High Dose (12 mg) Verinurad.~As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at visit 9
Study NCT03990363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Study treatments will be titrated in 3 steps: Low dose (100 mg), intermediate (200 mg) and High Dose ( 300 mg) Allopurinol
Study NCT03990363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Verinurad
Description: Matching Capsule
Study NCT03990363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Allopurinol
Description: Matching tablet
Study NCT02076867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Short-Term Dynamic Psychotherapy
Description: The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation and perpetuation of somatic symptoms. Treatment will be provided according to manualized recommendations. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and somatic presentation. The research protocol calls for the treatment duration to be initially agreed at 8 weeks and then reviewed. Treatment should be delivered as a maximum 20-session time-limited format. The first session is an extended 2-3 hour appointment; then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Treatment progress is reviewed, specifically at sessions 4 and 8 to clarify the goal and objectives of further sessions. Patients are informed of the maximum treatment length. Termination in fewer sessions is based upon agreement between therapist and patient.
Study NCT02076867 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Short-Term Dynamic Psychotherapy
Description: The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation and perpetuation of somatic symptoms. Treatment will be provided according to manualized recommendations. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and somatic presentation. The research protocol calls for the treatment duration to be initially agreed at 8 weeks and then reviewed. Treatment should be delivered as a maximum 20-session time-limited format. The first session is an extended 2-3 hour appointment; then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Treatment progress is reviewed, specifically at sessions 4 and 8 to clarify the goal and objectives of further sessions. Patients are informed of the maximum treatment length. Termination in fewer sessions is based upon agreement between therapist and patient.
Study NCT02076867 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Care As Usual (MCAU)
Description: This Medical Care As Usual (MCAU) was selected to control for both the role of emergency department care and family doctors care, as well as the passage of time and the natural emergence and reduction in symptoms before further intervention. Participants allocated to this group are advised that care will continue to be provided to them by the ED and they will be contacted with an appointment to see a therapist in 8 weeks should they so wish. They are advised to contact their family physician for routine care where necessary
Study NCT01535131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: palatoplasty
Description: procedure to close cleft palate
Study NCT01535131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: palatoplasty
Description: procedure to close cleft palate
Study NCT04177914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC)
Description: Since the early 1990s, ETV has become the main alternative to shunting for hydrocephalus. This procedure involves placing an endoscopic camera into the ventricles of the brain and creating a hole in the floor of the third ventricle to act as an internal bypass for obstructed CSF. The cauterization of choroid plexus (CPC) involves the use of a device to burn or cauterize tissue from the choroid plexus. The choroid plexus of the brain exists in the lateral ventricles, the third ventricle, and the fourth ventricle. Its main role is the production of CSF. The success of ETV alone is poor in infants, but when combined with CPC, improved results have been observed and ETV+CPC has become a safe viable option for these children.
Study NCT04177914 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventriculoperitoneal Shunt
Description: The most common treatment for hydrocephalus has been the insertion of a ventriculoperitoneal shunt, which has been in popular use for over 50 years. This consists of silastic tubing attached to a valve mechanism that runs subcutaneously from the head to the abdomen. It is one of the most common procedures performed by pediatric neurosurgeons.
Study NCT03612518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text and Voice Messages
Description: Participants in this study arm will periodically receive information regarding antenatal- and postnatal care and family planning services through text and voice messages from the fifth gestational month until the post-partum period of 42 days.
Study NCT03612518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Phone Call
Description: Participants in this study arm will receive information regarding antenatal- and postnatal care and family planning services through periodic interactive phone calls from the fifth gestational month until the post-partum period.
Study NCT02857660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body Electromyostimulation (exercise)
Description: 1.5 x 20 min/week (e.g. each Tuesday and every second Friday) with bipolar current, 85 Hz, 360 µs, rectangular mode, intermittent with 4 sec of current and 4 s of rest.
Study NCT02857660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: up to 1.5-1.7 g/kg bodymass/d of protein (whey protein)
Study NCT02857660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: up to 1.5-1.7 g/kg bodymass/d of protein (whey protein)
Study NCT02290366 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal prostate brachytherapy with Cesium-131
Study NCT02664779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arrhythmia diagnosis with the 10 steps method
Study NCT03565302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Subjects are treated with daily inhalation of formoterol
Study NCT03565302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: Subjects are treated with daily inhalation of terbutaline
Study NCT03565302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are treated with placebo
Study NCT01533181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01533181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01533181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linsitinib
Description: 150 mg given orally (PO) twice a day (BID)
Study NCT01533181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01533181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01533181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan Hydrochloride
Description: 1.5 mg/m\^2 intravenously (IV) or 2.3 mg/m\^2 orally (PO)
Study NCT03317678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioKefir
Description: BKP BioKefir (Lifeway Foods) is a lactose-free fermented milk product containing 12 different bacteria provided in a drink.
Study NCT03317678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-fermented milk
Description: A non-fermented milk drink.
Study NCT03704571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol
Description: In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.~In the control group, all the patients are given routine regimens.
Study NCT03704571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol
Description: In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.~In the control group, all the patients are given routine regimens.
Study NCT03052283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire Patient Reported Outcome Measure (PROM)
Description: non-interventional
Study NCT02950714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIN_NOW
Description: The Lupus interactive navigator (LIN) was developed to facilitate and support engagement and self-management for persons with lupus. It is a web-based program that provides access to relevant information, resources, support, and other tools to help them manage their illness. It is accessible by the Internet and compatible for use with computer, tablet, and mobile device. The content for the LIN was based on the results of focus group discussions and web-based surveys of persons with lupus and health care providers. Medical researchers, writers, designers and programmers worked with clinical experts affiliated with the Canadian Network for improved outcomes in Systemic Lupus Erythematosus (CaNIOS) and persons with lupus to provide the written content and interview videos.
Study NCT02950714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LIN_WAIT
Description: Usual care for three months prior to access to the LIN
Study NCT02847637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Participants received emicizumab prophylaxis subcutaneously at the specified dose for each arm. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant had the option to choose a preferred emicizumab dosing regimen among those permitted (i.e., emicizumab 1.5 mg/kg once every week \[QW\], 3 mg/kg once every 2 weeks \[Q2W\], or 6 mg/kg once every 4 weeks \[Q4W\]) and continue on that dosing regimen until discontinuation from the study.
Study NCT02847637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emicizumab
Description: Participants received emicizumab prophylaxis subcutaneously at the specified dose for each arm. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant had the option to choose a preferred emicizumab dosing regimen among those permitted (i.e., emicizumab 1.5 mg/kg once every week \[QW\], 3 mg/kg once every 2 weeks \[Q2W\], or 6 mg/kg once every 4 weeks \[Q4W\]) and continue on that dosing regimen until discontinuation from the study.
Study NCT02847637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor VIII (FVIII)
Description: FVIII was allowed to treat bleeds on an episodic basis, per the local prescribing information. Specific dosages of FVIII were not mandated in the study. Breakthrough bleeds were to be treated with the lowest FVIII dose expected to achieve hemostasis, which may have been lower than the participant's prior FVIII dose. To avoid bleeds before adequate emicizumab level is reached, patients in Arm D continued their regular FVIII prophylaxis until the second emicizumab loading dose. Concomitant routine FVIII prophylaxis was not permissible otherwise during the study.
Study NCT02847637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Factor VIII (FVIII)
Description: FVIII was allowed to treat bleeds on an episodic basis, per the local prescribing information. Specific dosages of FVIII were not mandated in the study. Breakthrough bleeds were to be treated with the lowest FVIII dose expected to achieve hemostasis, which may have been lower than the participant's prior FVIII dose. To avoid bleeds before adequate emicizumab level is reached, patients in Arm D continued their regular FVIII prophylaxis until the second emicizumab loading dose. Concomitant routine FVIII prophylaxis was not permissible otherwise during the study.
Study NCT02968654 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Restrictive Transfusion Strategy
Description: Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Restrictive Transfusion Strategy will receive blood transfusion whenever their Hb concentration is \< 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed.
Study NCT02968654 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liberal Transfusion Strategy
Description: Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Liberal Transfusion Strategy will receive blood transfusion whenever their Hb concentration is \< 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed.
Study NCT04435405 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: video footage analysis of group and individual behavioral processes.
Study NCT01362283 — intervention group
Intervention type: OTHER
Intervention: Blood Sampling
Description: Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
Study NCT01475019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Tablet, 120 mg, three times daily, for six months
Study NCT02664779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arrhythmia diagnosis with the 6 steps method
Study NCT02664779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arrhythmia diagnosis with the 4 steps method
Study NCT02918929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP 305
Study NCT02918929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match EDP 305
Study NCT01475019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: Tablet, 10 mg, once daily, for six months
Study NCT01475019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and physical exercise
Description: Hypocaloric diet and regular physical exercise
Study NCT02343978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711
Study NCT00005797 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: busulfan
Description: administered on Day -7 through Day -4. The total dose is 12.8 mg/kg
Study NCT00005797 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
Study NCT00479089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 25 mg/m2 IV over 30 minutes for 4 weeks, followed by 2 weeks off therapy.
Study NCT00005797 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: VP-16
Description: administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is >/= 150% of IBW, in which case adjusted body weight will be used.
Study NCT00005797 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Fractionated Total Body Irradiation (FTBI)
Description: FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.
Study NCT01862185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: semi-quantitative procalcitonin
Study NCT00465907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Carboplatin and Irinotecan
Description: Paclitaxel-60mg/m2 weekly for 3 weeks Carboplatin - AUC 1.5, weekly for 3 weeks Irinotecan - 60mg/m2, weekly for 3 weeks
Study NCT00479089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZD1839
Description: 250 mg by mouth daily, without break.
Study NCT00479089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Course #1: 3 doses of prophylactic Dexamethasone 4mg orally every 12 hours, starting the night before the Docetaxel infusion.~Course #2: If no hypersensitivity reactions and no significant fluid retention during course 1, the Dexamethasone is reduced to 4mg orally twice daily on the day of therapy.~Course #3 and subsequent courses: If no hypersensitivity reactions and no significant fluid retention during course 2, the Dexamethasone is reduced to 4mg orally one hour before treatment.
Study NCT01389479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral™
Description: Intramuscular, single dose
Study NCT01389479 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone®
Description: Intramuscular, single dose
Study NCT03338543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PENS
Description: percutaneous electrical nerve stimulation
Study NCT03338543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: transcutaneous electrical nerve stimulation
Study NCT03599856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TraceBook
Description: TraceBook offers the user intelligent dynamic clinical checklist that shows patient specific items to a specific user while being context aware.
Study NCT02831985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general practice follow-up
Description: Post-surgery follow-up by general practitioner
Study NCT02831985 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ear-nose-throat (ENT) specialist follow-up
Description: Post-surgery follow-up by ear-nose-throat (ENT) specialist
Study NCT01585350 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)
Description: Cohort 1 will be divided into three sub-groups and will receive:~* Group 1a: MELITAC 12.1 + lipopolysaccharide (LPS)~* Group 1b: MELITAC 12.1 + lipopolysaccharide (LPS) + Montanide adjuvant with vaccination #1~* Group 1c: MELITAC 12.1 + lipopolysaccharide (LPS) adjuvant + Montanide adjuvant with all vaccinations
Study NCT03751163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Oral Product
Description: Encapsulated tranexamic acid 250 mg
Study NCT03751163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroquinone 4% Cream
Description: Hydroquinone 4% Cream
Study NCT03751163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone 4% Cream
Description: Hydroquinone 4% Cream
Study NCT01040403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol (BI 1744) low
Description: olodaterol (BI 1744) low
Study NCT03751163 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen SPF 30
Study NCT01040403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low tiotropium bromide
Description: low tiotropium bromide
Study NCT01040403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol (BI 1744) high
Description: olodaterol (BI 1744) high
Study NCT03751163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen SPF 30
Study NCT03751163 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated placebo